Novartis bets $9.7bn on pivot to cardiovascular disease 25-Nov-2019 By Ben Hargreaves Novartis announces bolt-on acquisition of Medicines Co., which adds the latter company’s sole drug candidate, inclisiran, to its CVD pipeline.